Nitro Or Nitroso Bonded Directly To Amino Nitrogen (e.g., Nitramine, Nitrosamine, Nitro-urea, Etc.) Patents (Class 514/589)
-
Publication number: 20030078281Abstract: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an anti-tumor alkylating agent for inhibiting the growth of tumor cells and useful in the treatment of cancer.Type: ApplicationFiled: August 28, 2002Publication date: April 24, 2003Inventor: Mary Ellen Margaret Rybak
-
Publication number: 20030040526Abstract: The present invention provides a combination therapy using eflomithine (DFMO) and PCV (matulane, lomustine and vincristine) in the treatment of anaplastic gliomas. In contrast to the results seen with glioblastoma multiforme, anaplastic gliomas responded better to the combination of DFMO and PCV than to either the PCV combination or DFMO alone, extending patient survival by approximately two years.Type: ApplicationFiled: August 13, 2002Publication date: February 27, 2003Inventor: Victor A. Levin
-
Patent number: 6503948Abstract: A method for treating an organ donor prior to harvesting organ to reduce graft rejection in a recipient. An amount effective to reduce graft rejection of at least one compound selected from the group consisting of compounds having formulas I, II, III, IV, V, VI, and VII is administered to the organ donor: wherein Y is X is F or Cl; and the remaining groups are as defined in the specification.Type: GrantFiled: April 17, 2002Date of Patent: January 7, 2003Assignee: Southern Research InstituteInventors: Herbert M. Blatter, Donald R. Kahn, James R. Piper, John A. Secrist, III, Robert F. Struck, Carroll Temple
-
Publication number: 20020198264Abstract: This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone. Additionally, methoxyamine is contemplated for methods of treatment of cancer, wherein methoxyamine is used, in combination or in sequence, with other anticancer drugs or agents.Type: ApplicationFiled: February 19, 2002Publication date: December 26, 2002Applicant: Case Western Reserve UniversityInventors: Stanton L. Gerson, Lili Liu
-
Publication number: 20020169128Abstract: A method of reducing organ toxicity in a subject being administered a cytotoxic agent comprising concurrently administering with the cytotoxic agent erythropoietin (EPO), the EPO being administered in an amount effective to reduce pulmonary toxicity caused by the cytotoxic agent.Type: ApplicationFiled: April 5, 2002Publication date: November 14, 2002Inventors: Geroge Sigounas, Paul D. Mehlhop
-
Publication number: 20020123477Abstract: The present invention provides for improved methods of gene transfer, both in vitro and in vivo. By treating neoplastic cells with a DNA-damaging agent prior to transduction with a transgene, the expression of the transgene is improved up to about 3-fold over the expression seen in the absence of the DNA-damaging agent treatment. This effect is not dependent on the tumor cell type, the method of DNA transduction or type of DNA-damaging agent. The effect is most dramatic when the transduction is performed about 1-3 days following treatment with the DNA-damaging agent.Type: ApplicationFiled: August 3, 2001Publication date: September 5, 2002Applicant: Board of Regents, The University of Texas SystemInventors: Richard J. Cristiano, Dao Nguyen
-
Publication number: 20020077357Abstract: N-Substituted-N′-substituted urea derivatives represented by the following formula, analogs thereof or pharmaceutically acceptable salts thereof are herein provided. These compounds show a TNF-&agr; production inhibitory activity.Type: ApplicationFiled: October 4, 2001Publication date: June 20, 2002Inventors: Shiro Mita, Masato Horiuchi, Masakazu Ban, Hiroshi Suhara
-
Patent number: 6297281Abstract: The invention concerns a pharmaceutical composition containing, as active principle, at least one NO syntase inhibiting substance and at least one oxygen reactive form trapping substance, optionally with a pharmaceutically acceptable support. The invention also concerns a product containing at least one NO syntase inhibiting substance and at least one oxygen reactive form trapping substance as combined product of these active principles in separate form.Type: GrantFiled: March 2, 1999Date of Patent: October 2, 2001Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Pierre-Etienne Chabrier de Lassauniere, Dennis Bigg
-
Patent number: 6284747Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: GrantFiled: October 5, 2000Date of Patent: September 4, 2001Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6277835Abstract: The present invention provides methods for treating mammalian cancer tumors, preferably solid tumors, comprising administering to a mammal in need of such treatment an effective amount of a 1,2,4-benzotriazine oxide as defined in Formula I or pharmacologically acceptable salts of said compound; and administering to the mammal from about one half hour to about twenty-four hours after administering the 1,2,4-benzotriazine oxide an effective amount of a chemotherapy agent to which the tumor is susceptible. The invention also provides kits for treatment of such tumors which comprise a chemotherapy agent and a cytotoxicity-enhancing amount of a 1,2,4-benzotriazine oxide as defined in Formula I.Type: GrantFiled: April 26, 2000Date of Patent: August 21, 2001Assignee: The Board of Trustees of Leland Stanford Junior UniversityInventor: J. Martin Brown
-
Patent number: 6147060Abstract: A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, adriamycin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. The cytotoxic chemical compound and the squalamine may be administered by any suitable route. The first treatment procedure may take place prior to the second treatment procedure, after the second treatment procedure, or the two treatment procedures may take place simultaneously. In one example, the first treatment procedure (e.g., a one time intravenous dosage of BCNU) is completed before the second treatment procedure with squalamine begins.Type: GrantFiled: April 25, 1997Date of Patent: November 14, 2000Assignee: Magainin PharmaceuticalsInventors: Michael Zasloff, Jon Williams
-
Patent number: 6046234Abstract: This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.Type: GrantFiled: January 6, 1999Date of Patent: April 4, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Thomas J. Dodd
-
Patent number: 5792811Abstract: The invention is a primer composition, comprising(a) a polyester resin of a carboxylic acid and a glycol;(b) a polymethylene poly(phenyl isocyanate), diphenylmethane diisocyanate or a mixture thereof; and(c) bismuth octoatein a volatile solvent.The primer composition of the invention advantageously provides improved adhesion characteristics of metal-to-glass bonding when used to prime substrate, particularly painted metal substrate before the application of a urethane adhesive. The primer composition of the invention may also be used to prime other metal and glass surfaces for use with various adhesives.Type: GrantFiled: December 30, 1996Date of Patent: August 11, 1998Assignee: The Dow Chemical CompanyInventor: Shailesh S. Bhat
-
Patent number: 5780675Abstract: The invention provides deoxygossylic compounds having useful biological activities, and methods for the synthesis of these and related compounds. The invention further provides valuable intermediates for the synthesis of the compounds, and pharmaceutical compositions containing biologically active compounds according to the invention.Type: GrantFiled: April 28, 1995Date of Patent: July 14, 1998Assignee: The University of New MexicoInventors: Robert D. Royer, Lorraine M. Deck, David L. VanderJagt
-
Patent number: 5776925Abstract: Methods for cancer chemosensitization are provided. Texaphyrins are new chemosensitizers for enhancing the cytotoxicity of chemotherapeutic agents. The enhancement appears to be P-glycoprotein-independent since texaphyrins are effective in both a P-glycoprotein-expressing and a P-glycoprotein -nonexpressing cell line. Methods are provided for the treatment of cancers such as leukemia, lymphoma, carcinoma, and sarcoma using a texaphyrin as a chemosensitizer.Type: GrantFiled: January 25, 1996Date of Patent: July 7, 1998Assignee: Pharmacyclics, Inc.Inventors: Stuart W. Young, Richard A. Miller
-
Patent number: 5731325Abstract: A method for treatment of malignant melanoma by administering an effective amount of thalidomide alone or in combination with other anti-melanoma drugs.Type: GrantFiled: June 6, 1995Date of Patent: March 24, 1998Assignee: Andrulis Pharmaceuticals Corp.Inventors: Peter J. Andrulis, Jr., Murray W. Drulak
-
Patent number: 5691307Abstract: Novel O.sup.6 -substituted guanine compounds and pharmaceutical compositions thereof are useful for effectively reducing O.sup.6 -alkylguanine-DNA alkyltransferase (AGT). The novel compounds are useful for treating tumors and when used with anti-neoplastic alkylating agents enhance the chemotherapeutic treatment of tumor cells in a host.Type: GrantFiled: June 7, 1994Date of Patent: November 25, 1997Assignees: The United States of America as represented by the Department of Health and Human Services, The Penn State Research Foundation, Arch Development CorporationInventors: Robert C. Moschel, M. Eileen Dolan, Anthony E. Pegg, Mark G. McDougall, Mi-Young Chae
-
Patent number: 5614550Abstract: Compounds of formula (I) are provided: ##STR1## wherein: R.sup.1 represents an alkyl group; or a group of formula (II), (III), (IV) or (V): ##STR2## and wherein the groups R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen or various organic groups; and pharmaceutically acceptable salts thereof; as well as methods for the preparation of such compounds and their use in the treatment and prophylaxis of hypercholesteremia and arteriosclerosis.Type: GrantFiled: February 27, 1996Date of Patent: March 25, 1997Assignee: Sankyo Company, LimitedInventors: Akira Yoshida, Koza Oda, Sadao Ishihara, Fujio Saito, Hiroyuki Koike, Teiichiro Koga, Eiichi Kitazawa, Hiroshi Kogen, Ichiro Hayakawa
-
Patent number: 5578583Abstract: Microemulsions, similar in chemical composition to the lipid portion of low density lipoprotein (LDL), but not containing the protein portion, can be used as vehicles for the delivery of chemotherapeutic or diagnostic agents to neoplastic cells, while avoiding normal cells. When these artificial microemulsion particles are injected in the bloodstream or incubated with plasma, they incorporate plasma apolipoproteins on to their surface. The microemulsions can then be incorporated into cells via receptors for LOL and deliver molecules which are incorporated in the core or at the surface of the microemulsion.Type: GrantFiled: February 13, 1995Date of Patent: November 26, 1996Assignee: Fundac ao E. J. ZerbiniInventor: Raul C. Maranh ao
-
Patent number: 5534529Abstract: Compounds of formula (I) are provided: ##STR1## wherein: R.sup.1 represents an alkyl group; or a group of formula (II), (III), (IV) or (V): ##STR2## and wherein the groups R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen or various organic groups; and pharmaceutically acceptable salts thereof; as well as methods for the preparation of such compounds and their use in the treatment and prophylaxis of hypercholesteremia and arteriosclerosis.Type: GrantFiled: June 28, 1994Date of Patent: July 9, 1996Assignee: Sankyo Company, LimitedInventors: Akira Yoshida, Koza Oda, Sadao Ishihara, Takashi Kasai, Fujio Saito, Hiroyuki Koike, Teiichiro Koga, Eiichi Kitazawa, Hiroshi Kogen, Ichiro Hayakawa
-
Patent number: 5264425Abstract: Salts of glycosaminoglycans (heparin, its fractions or fragments which are supersulfated, dermatan sulfate, heparan sulfate, and modified heparins) with bases of formula (I), ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 represent H, alkyl, or cycloalkyl; R.sub.5 and R.sub.6 represent H, or alkyl; R.sub.7 and R.sub.8 represent H or alkyl; n and m are integers from 1-4 and X is --O--CO--O--, which salts have the pharmacological properties of the glycosaminoglycans themselves, and are orally and rectally administrable.Type: GrantFiled: November 15, 1990Date of Patent: November 23, 1993Assignee: Italfarmaco S.p.A.Inventors: Alma Dal Pozzo, Maurizio Acquasaliente, Giancarlo Sportoletti, Monique Sarret, Paolo Ferruti, Francesco De Santis
-
Patent number: 5034221Abstract: A topical agent and method for the treatment and prevention of pseudofolliculitis barbae, commonly known as "razor bumps", is effected by the topical application to beard areas of the face of a combination of acetylsalicylic acid, corn starch, isopropyl alcohol, and aloe vera.Type: GrantFiled: June 22, 1989Date of Patent: July 23, 1991Inventors: Steven E. Rosen, Robert M. Thomas
-
Patent number: 5023271Abstract: A method for parenteral administration of fat-soluble pharmaceuticals and vitamins using microemulsions is disclosed. The microemulsions are comprised of a naturally occurring amphipatic substance and a hydrophobic lipid along with the active ingredient, are size selected for 300-1000 .ANG. pseudomicelles, and permit safe intravenous injection of the active ingredient. Levels of the active ingredient in the various lipoprotein fractions of serum appear to mimic the natural distribution of the administered drug if taken orally.Type: GrantFiled: August 13, 1985Date of Patent: June 11, 1991Assignee: California Biotechnology Inc.Inventors: Jean-Louis Vigne, John P. Kane
-
Patent number: 5001158Abstract: Compounds having the general formula (I), ##STR1## wherein X and Y represent individually H or --NO, at least one of them being a group-NO, n is 0, 1 or 2, R represents hydrogen, an aliphatic, cycloaliphatic, cycloaliphatic-alkyl, aryl or aralkyl radical, or a group of formula, ##STR2## wherein R.sub.1 is a lower alkyl radical or an aryl, all these radicals being optionally substituted. The present invention also relates to the compounds hereabove defined in the form of mixtures of their position isomers. Furthermore, the present invention discloses processes for preparing such compounds, as well as compositions, useful particularly in anticancerous chemotherapy, containing at least one of said compounds as an active principle.Type: GrantFiled: January 2, 1990Date of Patent: March 19, 1991Assignee: Centre National de la Recherche ScientifiqueInventors: Jean-Claude Madelmont, Denise Godeneche, Marie-France Moreau, Daniel Parry, Gustin Meyniel, Joel Oiry, Jean-Louis Imbach
-
Patent number: 4952607Abstract: The present invention relates to copper complexes exhibiting superoxide dismutase-like activity in mammalian cells. The copper complexes, which act as superoxide radical (O.sub.2.sup.-) scavengers, are used in treating cancer by replacing the lost superoxide dismutase activity which characterizes tumor systems. The low molecular weight and lipid solubility of the copper complexes facilitate penetration of cell membranes. Depending upon the specific type of copper complex used, treatment may result in decreased tumor growth, increased survival of the host organism, decreased tumor metastasis or induced morphological differentiation of cancerous cells. The copper complexes used according to the invention include copper salicylate complexes, their solvates as well as mixtures thereof. A method for the treatment of cancer using these copper complexes is also disclosed.Type: GrantFiled: January 30, 1986Date of Patent: August 28, 1990Assignee: International Copper Research Association, Inc.Inventors: John R. J. Sorenson, Larry W. Oberley
-
Patent number: 4900548Abstract: This invention relates to the use of diethylcarbamazine (DEC), its analogs, homologs, and pharmaceutically acceptable salts thereof as an antiviral agent. This invention further relates to the use of DEC in in vivo diagnosis to increase antibodies to a particular disease; to the use of DEC in in vitro serologic assays to increase efficacy; and to the use of DEC as a vaccine adjuvant.Type: GrantFiled: November 13, 1987Date of Patent: February 13, 1990Assignee: Harvard UniversityInventor: Lynn W. Kitchen
-
Patent number: 4623662Abstract: This invention is concerned with ureas and thioureas which may be represented by the formula: ##STR1## wherein X represents at least one substituent selected from the group consisting of (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkenyl, (C.sub.1 -C.sub.4)alkynyl, phenoxy, mercapto, amino, (C.sub.1 -C.sub.4)alkylamino, di-(C.sub.1 -C.sub.4)alkylamino, halo, trihalomethyl, (C.sub.1 -C.sub.4)alkanoyl), benzoyl, (C.sub.1 -C.sub.4)alkanamido, haloacetamido, nitro, cyano, carboxy, (C.sub.1 -C.sub.4)carboalkoxy, carbamoyl, sulfamyl, methylenedioxy, phenyl, orthophenylene, tolyl, benzyl, halobenzyl, methylbenzyl; Y is selected from the group consisting of oxygen and sulfur; R.sub.1 and R.sub.2 are different and are independently selected from the group consisting of (C.sub.4 -C.sub.12)alkyl, (C.sub.4 -C.sub.12)alkenyl, (C.sub.4 -C.sub.12)alkynyl, (C.sub.4 -C.sub.12)cycloalkylalkyl, (C.sub.7 -C.sub.14)aralkyl, and (C.sub.7 -C.sub.Type: GrantFiled: May 23, 1985Date of Patent: November 18, 1986Assignee: American Cyanamid CompanyInventor: Vern G. De Vries